Alzheimer’s

At the Vanderbilt University School of Medicine Basic Sciences, researchers are advancing neuroscience discoveries through molecular biology, pharmacology, drug discovery, and more. Their work seeks to understand how the brain functions in health and disease, identify new therapeutic targets, and develop innovative treatments for conditions ranging from Alzheimer’s and addiction to depression and epilepsy. Read More

We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea... Read More

Researchers at the Warren Center for Neuroscience Drug Discovery have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

The Vanderbilt Memory and Alzheimer's Center hosted its fifth Annual Vanderbilt Alzheimer’s Disease Research Day on April 10 with the theme of “big data.” Aside from presentations from faculty from across campus and the School of Medicine Basic Sciences, the day featured data blitzes, a keynote presentation, and a poster reception with more than 45 posters. Read More

Ethan Lippmann, associate professor of chemical and biomolecular engineering and biomedical engineering, has won a Collaborative Pairs Pilot Project Award from the Chan Zuckerberg Initiative (CZI) to create a more effective way for the immune system to fight against neurodegenerative diseases like Alzheimer’s. Read More

Vanderbilt engineering professor Justus Ndukaife is leading innovative research that more effectively traps nanosized extracellular vesicles and particles to analyze their roles in cancer, and neurodegenerative diseases. Read More

Reported June 13 in Neurology, an Alzheimer’s disease risk study from Vanderbilt University Medical Center measures significantly reduced risk associated with healthy lifestyles, including non-smoking, leisure-time exercise, low-to-moderate alcohol consumption, adequate sleep and healthy diet. Read More